Biopure delays US submission for blood substitute:
This article was originally published in Clinica
Biopure has delayed by around six months plans to file a marketing application in the US for its blood substitute, Hemopure. The company previously said it would file a biologic licence application (BLA) for the product to the FDA by the end of 2001. The delay comes as a result of the company's plans to increase the production capacity of its Cambridge, Massachusetts manufacturing plant, a move that calls for additional facility and process validation requirements for the BLA filing. As a result, Biopure is targeting the filing for mid-2002 or sooner, depending on discussions with the FDA.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.